Abstract
Medicine individualisation remains constrained by the limited availability of age-appropriate strengths and by extemporaneous practices that can compromise dose consistency. Direct powder extrusion (DPE) 3D printing offers an alternative manufacturing method for personalised medicine, without introducing solvents, complex preparation, or post-processing that challenge pharmacy adoption. However, achieving uniform weight and drug content for small objects (e.g., paediatric-friendly minitablets) and lowering the preparation temperature remain challenges for extrusion-based 3D printing technologies.In this work, we introduce a facile low-temperature DPE 3D printing strategy to manufacture carvedilol minitablets, starting from carvedilol powder or licensed tablets as starting materials, using a high-precision pharmaceutical-grade 3D printer. Methacrylate-based polymers, polyethylene glycol, and glyceryl monostearate were used to enable extrusion at 70-75°C. When the 3D printer was challenged with minute-dimensional designs, it was possible to manufacture batches of minitablets up to 2 mm in diameter with 0.8 mm in thickness. The lowest minitablet weight variation was 1.48%, achieved with an optimal diameter of 3.6 mm and a thickness of 1.6 mm; this was also reflected in the drug content uniformity (within ±5%). The immediate-release batch met British Pharmacopoeia requirements (>80% in 45 min), whereas the extended-release formulations exhibited prolonged drug release (>50% in 24 h).These findings extend DPE 3D printing to a viable manufacturing platform for accurate, low-dose small solid units, such as minitablets. By coupling a GMP-compliant 3D printer with a simplified preparation workflow, this work provides a realistic blueprint for integrating DPE-enabled personalised minitablets into hospital pharmacy and point-of-care settings.